News | July 22, 2021
Gland Pharma Q1FY22 consolidated PAT rises to Rs. 350.65 Cr
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
This will enable Mangalam to reduce its reliability on Chinese imports for this product and also help to maintain an uninterrupted supply chain to a great extent
Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.
State governments and UTs have been asked to monitor proper distribution within the state/UT covering government and private hospitals
The facility is expected to be completed in 2024
The Department of Pharmaceuticals launched the PLI scheme for promoting domestic manufacturing of bulk drugs, with a financial outlay of Rs. 6,940 crore across 53 APIs over 6 years
Essential medicines were made available to more than 150 countries around the world during the pandemic
Subscribe To Our Newsletter & Stay Updated
